Biosimilars of adalimumab: the upcoming challenge in IBD

References

• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management. J Crohn colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohn’s Colitis. 2017;11(1):3–25.
   Google Scholar
• Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–478.
   PubMedGoogle Scholar
• Research and markets global monoclonal antibodies market - by type, application, region - market size, demand forecasts, company profiles, industry trends and updates (2017–2023). [cited Aug 17]. Available from: https://www.researchandmarkets.com/research/mmpjv5/global_131_33?w=4
   Google Scholar
• Technavio global anti-inflammatory therapeutics market 2017-2021. [cited Aug 17]. Available from: https://www.technavio.com/report/global-anti-inflammatory-therapeutics-market?utm_source=t2&utm_medium=bw&utm_campaign=businesswire
   Google Scholar
• www.statista.com potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros). [cited Aug 17]. Available from: https://www.statista.com/statistics/700008/potential-savings-due-to-biosimilars-in-eu5-and-us/
   Google Scholar
• European Medicines Agency Inflectra. [cited Sept 29]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002778/smops/Positive/human_smop_000531.jsp&mid=WC0b01ac058001d127
   Google Scholar
• European Medicines Agency Remsima. [cited Sept 29]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/smops/Positive/human_smop_000532.jsp&mid=WC0b01ac058001d127
   Google Scholar
• European Medicine Agency Flixabi. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004020/human_med_001980.jsp&mid=WC0b01ac058001d124
   Google Scholar
• European Medicine Agency Zessly. [Aug 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004647/WC500249650.pdf
   Google Scholar
• Annese V, Vecchi M. Use of biosimilars in inflammatory bowel disease: statements of the Italian group for inflammatory bowel disease. Dig Liver Dis. 2014;46(11):963–968.
   PubMedGoogle Scholar
• Arguelles-Arias F, Barreiro-de-Acosta M, Carballo F, et al. Joint position statement by Spanish society of gastroenterology and Spanish society of pharmacology on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig. 2013;105(1):37–43.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohn’s Colitis. 2017;11(1):26–34.
   Google Scholar
• Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohn’s Colitis. 2013;7(7):586–589.
   Google Scholar
• Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immune-mediated disease: A joint Italian society of rheumatology (SIR), Italian society of dermatology (SIDeMaST), and Italian group of inflammatory bowel disease (IG-IBD) position paper. Autoimmun Rev. 2014;13(7):751–755.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency Biosimilar medicines. [cited Aug 21]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp&mid=WC0b01ac0580bb8fda
   Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis organization. J Crohn’s Colitis. 2014;8(11):1548–1550.
   Google Scholar
• Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–3196.
   PubMed Web of Science ®Google Scholar
• Farkas K, Rutka M, Balint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis - experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257–1262.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Lovasz BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohn’s Colitis. 2016;10(2):133–140.
   Google Scholar
• Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60(4):951–956.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim YH, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35–44.
   PubMedGoogle Scholar
• Smits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohn’s Colitis. 2016;10(11):1287–1293.
   Google Scholar
• Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among european Crohn’s colitis organization [ECCO] Members: an updated survey. J Crohn’s Colitis. 2016;10(11):1362–1365.
   Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23(2):233–243.
   PubMed Web of Science ®Google Scholar
• Bergqvist V, Kadivar M, Molin D, et al. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756284818801244.
   Web of Science ®Google Scholar
• Fiorino G, Correale C, Radice S, et al. Letter: immunogenicity of infliximab originator vs. Aliment Pharmacol Ther. 2017;46(9):903–905.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Ruiz-Arguello MB, Maguregui A, et al. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. CT-P13 in IBD patients. Inflamm Bowel Dis. 2018;24(3):601–606.
   PubMed Web of Science ®Google Scholar
• Norman P. Humira: the impending patent battles over adalimumab biosimilars. Pharm Pat Anal. 2016;5(3):141–145.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency Humira - EPAR Scientific Discussion. [cited Aug 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000481/WC500050867.pdf
   Google Scholar
• European Medicine Agency Amgevita - Public Assessment Report. [Aug 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004212/WC500225277.pdf
   Google Scholar
• European Medicine Agency Solymbic - Public Assessment Report. [cited Aug 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004373/WC500225367.pdf
   Google Scholar
• European Medicine Agency Cyltezo - Public Assessment Report. [cited Aug 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004319/WC500238609.pdf
   Google Scholar
• European Medicine Agency Hyrimoz - Public Assessment Report. [cited Aug 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004320/WC500252824.pdf
   Google Scholar
• European Medicine Agency Imraldi - Public assessment report. [cited Aug 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004279/WC500233922.pdf
   Google Scholar
• Liu J, Eris T, Li C, et al. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30(4):321–338.
   PubMed Web of Science ®Google Scholar
• Velayudhan J, Chen YF, Rohrbach A, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30(4):339–351.
   PubMed Web of Science ®Google Scholar
• Kaur P, Chow V, Zhang N, et al. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76(3):526–533.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–1102.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;177(6):1562–1574.
   PubMed Web of Science ®Google Scholar
• Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679–1687.
   PubMed Web of Science ®Google Scholar
• Cohen S, Pablos JL, Wang H, et al. ABP 501 biosimilar to adalimumab: final safety, immunogenicity, and efficacy results from an open-label extension study. Ann Rheum Dis. 2017;76(supplement 2):834.
   Google Scholar
• Wynne C, Altendorfer M, Sonderegger I, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE(R)-PK) in healthy subjects. Expert Opin Investig Drugs. 2016;25(12):1361–1370.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77(6):914–921.
   PubMed Web of Science ®Google Scholar
• Dasilva A, Kronthaler U, Hofmann HP, et al. Comparison of Nonclinical Pharmacology, Pharmacodynamics and E. Arthritis Rheumatol. 2016;68(Supplement):10.
   Google Scholar
• Schuck E, Jauch J, Balfour A, et al. Open-label, single-dose, parallel-group trial to determine the pharmacokinetics, safety and immunogenicity of GP2017, a proposed adalimumab biosimilar, following a single subcutaneous injection by an autoinjector or prefilled syringe in healthy male subjects. Arthritis Rheumatol. 2016;68(Supplement 10). [cited 2018 Dec 31]. Available from: https://acrabstracts.org/abstract/a-randomized-open-label-single-dose-parallel-group-trial-to-determine-the-pharmacokinetics-safety-and-immunogenicity-of-gp2017-a-proposed-adalimumab-biosimilar-following-a-single-subcutaneous-in/
   Google Scholar
• Blauvelt A, Lacour JP, Fowler JF Jr., et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–631.
   Web of Science ®Google Scholar
• Shin D, Lee Y, Kim H, et al. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther. 2017;42(6):672–678.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70(1):40–48.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. Arthritis Rheumatol. 2018;70(6):832–840.
   PubMed Web of Science ®Google Scholar
• Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohn’s Colitis. 2016;10(3):239–254.
   Google Scholar
• Armuzzi A, Fiorino G, Variola A, et al. The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy. Inflamm Bowel Dis. 2018. doi: 10.1093/ibd/izy264. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar